News on proteomics applications for clinical use in genetics, genomics, and molecular diagnostics.
The company will test a peptide array approach that it believes can identify MSI-high, immunotherapy-responsive individuals more cheaply and easily than existing tests.
For the first time ever, the center is funding the development of diagnostic systems — specifically for the development of three devices to detect the infection.
The company's commercial testing continues to focus on patients with identified lung nodules, but the new data is the strongest yet to support a shift to upfront cancer detection.
The company announced that it would begin offering seven proteomic tests at Colorado doctors' practices with up to four more to launch by the end of the year.
The Tokyo-based firm said it will use the funding to support prototyping and commercialization of its mass spectrometry and optical spectroscopy instruments.
